



2026 Newborn Screening and Genetics

Tandem Mass Spectrometry Follow-Up Workshop

August 10 – 14, 2026

APHL Headquarters

7700 Wisconsin Avenue, Suite 1000
Bethesda, MD 20814

This meeting is sponsored by the Association of Public Health Laboratories

Purpose

This intensive five-day course assumes a basic understanding of newborn screening follow-up and metabolic biochemistry. Coursework will begin with a review of the principles of tandem mass spectrometry (MS/MS), diagnostic patterns in results, cut-offs, biochemical pathways, diagnostic follow-up and biochemical and clinical features of metabolic disorders. Each day will cover interpretive skills and diagnostic follow-up of certain disorders detectable through MS/MS screening including amino acid disorders, urea cycle disorders, fatty acid oxidation disorders, organic acid disorders, peroxisomal and lysosomal disorders.

The course content will be shared through didactic lectures and group discussions. Students learned knowledge will be assessed through quizzes and homework assignments. Successful course performance will be recognized with a certificate of course completion and continuing education units will be available.

Objectives

After completing this workshop, participants will be able to interpret the results obtained from MS/MS analysis of dried blood spots for amino acidopathies and urea cycle disorders, fatty acid oxidation disorders, organic acid disorders, peroxisomal and lysosomal disorders; perform a risk assessment based upon the analyte values and expected ranges, along with demographic information; describe the biochemical and clinical features of the metabolic disorders; learn the appropriate follow-up tests for confirmation of screening results and differential diagnosis; and understand the importance of continued long-term follow-up after diagnosis.

Disclosures

There is neither presence of conflict of interest nor commercial and sponsorship support among planners, faculty, or moderators for this workshop.

Non-Endorsement of Products

As an Accredited Provider of Continuing Education (CE) Credits for Health Education (CHES), Nursing (CNE), Medicine (CME), and Public Health (CPH) the American Public Health Association Center for Professional Development (CPD) Unit and its respective Continuing Education accrediting organizations do not endorse any products or services that are displayed or referred to in conjunction with this activity and are not responsible for the actual presentation of content during scientific sessions.

Policy on Disclosures to Learners

The Association of Public Health Laboratories strives to ensure balance, independence, objectivity and scientific rigor in all of its educational programs. All planners, faculty members, moderators, discussants, panelist and presenters participating in this program have been required to disclose any real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of this program. This includes relationships with pharmaceutical companies, biomedical device manufacturers or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is to identify openly any conflict of interest so that the attendees may form their own judgments about the presentation with full disclosure of the facts. In addition, faculty is expected to openly disclose any off-label, experimental and/or investigational uses of drugs or devices in their presentation. Disclosures, Conflict of Interest (COI) and Resolution of COI policies are available via the APHA's website and in the printed program.

Nursing (CNE) Accreditation

This nursing continuing professional development activity was approved by the American Public Health Association's Public Health Nursing Section Approver Unit, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.

Consent to Use Photographic Images

Registration and attendance at or participation in APHL Meetings and other activities constitutes an agreement by the registrant to APHL's use and distribution (both now and in the future) of the registrant's or attendee's image or voice, without compensation, in photographs, videotapes, electronic reproductions and audiotapes of such events and activities.

Well-Being

To ensure the health and well-being of everyone participating in this meeting, we kindly remind you to prioritize your health and that of others when deciding whether to attend in person meetings, especially if you are feeling unwell.

If you are experiencing any symptoms of illness or have been in contact with someone who is sick, we strongly encourage you to participate remotely or to reschedule your participation in the meeting. Your health and safety are our top priorities, and we appreciate your cooperation in maintaining a healthy work environment for all.

Contact

Noah Sinangil
Senior Specialist, Newborn Screening and Genetics
Email: noah.sinangil@aphl.org
Phone: 240.485.2336

AGENDA

Day 1	Monday August 10, 2026	
8:30 – 9:00 am 30 minutes	Arrival and Breakfast	
9:00 – 9:30 am 30 minutes	Welcome, Opening Remarks, and Introductions Scott Becker, MS, Chief Executive Officer, APHL Jelili Ojodu, MPH, Senior Director, Newborn Screening & Genetics, APHL Patrice K. Held, PhD, PhD FACMG, Newborn Screening Program Manager, Oregon State Public Health Laboratory	
9:30 – 9:45 am 15 minutes	Pre-Assessment and Review	Review
9:45 – 10:15 am 30 minutes	Brief History of Newborn Screening (NBS) and How It Was Transformed By Tandem Mass Spectrometry (MS/MS)	Lecture
10:15 – 10:45 am 30 minutes	Fundamentals of Liquid Chromatography (LC) and MS/MS - How does the MS/MS work? - Different scan functions to look for amino acids (AA), acylcarnitines (AC), and other analytes.	Lecture
10:45 – 11:00 am 15 minutes	Break	
11:00 – 11:30 am 30 minutes	Analyte Quantitation in NBS Using MS/MS - How analyte values are calculated. - Use of stable isotopes	Lecture
11:30 – 12:00 am 30 minutes	From Punch to Analysis: Laboratory Workflow Step by step description of the common laboratory workflows for amino acid (AA) & acylcarnitine (AC) analysis	Lecture
12:00 – 1:00 pm 60 minutes	Lunch	
1:00 – 2:00 pm 60 minutes	Basis of Metabolism In fed and fasting states, how and when does the body metabolize protein, carbohydrates, and fats?	Lecture

2:00 – 2:30 pm 30 minutes	Metabolism and Diet Discussion of metabolism and diet; ways in which metabolism is altered by dietary changes	Lecture
2:30 – 3:00 pm 30 minutes	Review of Central Dogma and Inheritance Patterns for Genetic Conditions - Central dogma, correlating the deoxyribonucleic acid (DNA) to the protein definition to the elevation of analytes measured in the laboratory - Autosomal recessive (AR) and X-Linked inheritance patterns	Lecture
3:00 – 3:15 pm 15 minutes	Break	
3:15 – 4:00 pm 45 minutes	Tell Me About Your Program: Testing Algorithms and Reporting Workflows	Discussion
4:00 – 4:30 pm 30 minutes	Lecture and Discussion Recap - Review concepts presented - Question and answer	Review
6:00 pm	Group Dinner Sponsored by Association of Public Health Laboratories	
Day 2	Tuesday August 11, 2026	
8:30 – 9:00 am 60 minutes	Breakfast	
9:00 – 10:30 am 90 minutes	Amino Acid (AA) and Urea Cycle Disorders - All Recommended Uniform Screening Panel (RUSP) conditions including guanidinoacetate methyltransferase (GAMT) deficiency and ornithine transcarbamylase (OTC) deficiency - Pathway, clinical presentation, treatment - NBS profile review of conditions presented (1st and 2nd tier)	Lecture
10:30 – 10:45 am 15 minutes	Break	
10:45 – 12:00 pm 75 minutes	Organic Acidemia (OA) Disorders - All RUSP conditions - Pathway, clinical presentation, treatment - Newborn screening profile review of conditions presented (1st and 2nd tier)	Lecture

12:00 – 1:00 pm 60 minutes	Lunch
1:00 – 2:00 pm 60 minutes	Fatty Acid Oxidation (FAO) Disorders and the Carnitine Cycle Lecture • All RUSP conditions • Pathway, clinical presentation, treatment • Newborn screening profile review of conditions presented (1st and 2nd tier)
2:00 – 2:30 pm 30 minutes	Lecture and Discussion Recap Review • Review concepts presented • Question and Answer
2:30 – 2:45 pm 15 minutes	Break
2:45 – 3:30 pm 45 minutes	Timeliness in NBS and Importance of risk assessment Lecture • Why is timeliness important? • Define risk assessment (borderline versus panic)
3:30 – 4:00 pm 30 minutes	Confirmatory Testing and Basic Laboratory Tests Lecture • Diagnostic testing performed in the clinical biochemical genetics laboratory • Plasma AA, urine OA, plasma AC, and other analyte specific testing
4:00 – 4:30 pm 30 minutes	Case Presentations and Clinical Vignettes Discussion
Day 3	Wednesday August 12, 2026
8:30 – 9:00 am 30 minutes	Breakfast
9:00 – 9:45 am 45 minutes	Lysosomal Disorders Lecture • Role of the lysosome • Metabolism of macromolecules • Pompe, MPS I, MPS II, Krabbe, MLD • Pathway, clinical presentation (mild, severe, late onset) treatment
9:45 – 10:30 am 45 minutes	Screening for Lysosomal Disorders Lecture • Step-by-step description of the common laboratory workflow for lysosomal disorders • Enzyme activity assessment combined with higher-tier testing, either molecular or biochemical testing • How to handle pseudo deficiencies and variants of unknown significance (VUS)

10:30 – 10:45 am 15 minutes	Break	
10:45 – 11:30 am 45 minutes	Screening for X-linked adrenoleukodystrophy (XALD) • Role of the peroxisome • Pathway, clinical, presentation, treatment	Lecture
11:30 – 12:00 pm 60 minutes	Premature Babies and Influence on Profiles • Influence of antibiotics, dietary interventions, other neonatal conditions	Lecture
12:00 – 12:30 pm 30 minutes	Result Review and Profiles • Practice reviewing profiles, assessing risk	Discussion
12:30 pm	Free Afternoon	
Day 4	Thursday August 13, 2026	
8:30 – 9:00 am 60 minutes	Breakfast	
9:00 – 10:30 am 90 minutes	Long-Term Follow-Up (LTFU) • Share experiences of states who are actively engaged in LTFU • Definitions of and barriers to LTFU • Address where short-term follow-up (STFU) stops and LTFU starts, especially for late onset conditions. • NewSTEPs LTFU Workgroup, Review of process measures and the Feasibility Pilot Study	Lecture
10:30 – 11:00 am 30 minutes	Tell Me About Your Program: Long-Term Follow-Up (LTFU) • What successes has your state LTFU program achieved? • What challenges has your program encountered?	Discussion
11:00 – 11:15 am 15 minutes	Break	
11:15 – 12:15 pm 60 minutes	Downstream Clinical Implications of Newborn Screening: A Genetic Counselor's Perspective • Example cases: X-linked conditions, false negatives, maternal conditions • Social determinants of health and how it impacts follow-up care	Lecture
12:15 – 1:00 pm 45 minutes	Lunch	

1:00 – 2:00 pm 60 minutes	Uncertainty in NBS and the Experience of Families Lecture
2:00 – 2:45 pm 45 minutes	Tell Me About Your Program: Result Notification and Communication Discussion • Share your experiences of uncertainty in NBS • Discuss challenges and barriers in reporting and communicating results
2:45 – 3:00 pm 15 minutes	Break
3:00 – 3:30 pm 30 minutes	On the Horizon Lecture • New conditions, increase in multiplexing and higher throughputs • Machine learning/artificial intelligence (AI) for data analysis • Research Initiatives (i.e., Screen Plus)
3:30 – 4:00 pm 30 minutes	Role of the Centers for Disease Control and Prevention (CDC) in Support of NBS programs Lecture
4:00 – 4:30 pm 30 minutes	Ask the Expert Discussion
Day 5	Friday August 14, 2026
8:30 – 9:00 am 30 minutes	Breakfast
9:00 – 10:00 am 60 minutes	Quality Assurance (QA) within NBS Programs Lecture • Laboratory quality assurance (QA) activities • Clinical Laboratory Improvement Amendments (CLIA) Standards and College of American Pathologists (CAP) Accreditation • Guidance from the Clinical Laboratory Standards Institute (CLSI) • Defining cutoffs and cutoff review • Investigation of false negatives
10:00 – 11:00 am 60 minutes	NewSTEPs Quality Assurance (QA) within NBS Follow-Up Lecture • NewSTEPs Specimen Metrics • NewSTEPs Case Metrics • NewSTEPs Screen Positive Study
11:00 – 11:15 am 15 minutes	Break

11:15 – 11:45 pm 30 minutes	Tell Me About Your Program: Quality Assurance and Management Discussion • What quality assurance practices are utilized in your laboratory? • Share your quality management plan
11:45 – 1:00 pm 75 minutes	Post-Test and Recap Review • Boxed Lunch • Review of key concepts
1:00 pm	Adjourn